Abstract 3565
Background
Pooled analyses from 2 phase III trials of patients (pts) with metastatic breast cancer (mBC) treated with eribulin (E) versus other chemotherapy showed improved overall survival (OS) favoring E. Subsequent subgroup analyses, including pts with visceral metastases (VM), also showed improved OS when treated with E. Current 3rd line mBC chemotherapy options include E, gemcitabine (G) and capecitabine (C), among others. This study evaluated 1-year (yr) OS in a real world setting among mBC pts with VM treated with E, G, or C in a US cancer center network.
Methods
This retrospective study investigated pts with mBC with biopsy proven VM (liver and/or lung), treated with E, G, or C in 3rd line chemotherapy from 1/1/2012 to 11/1/2018. Electronic health records and cancer registry data were used to detect differences in OS (number of mons from start of 3rd line until death). Univariate and multivariate analyses of 1-yr survival between E, G, and C were conducted using Kaplan Meier (KM) and Cox proportional hazard (CPH) models respectively.
Results
Of 1,828 mBC pts, 1,417 had VM, and 443 (27.5% triple negative, 13.7% HER2+ and 51.9% ER+/PR+) received 3rd line therapy with E = 229 (51.7%), G = 134 (30.2%) or C = 80(18.1%). On average, E, G, and C pts did not differ by age, ethnicity, BMI or ECOG score (categorized as good [0-1] and poor [>2]), but E pts had higher mean income compared to G or C. 1-yr KM survival analyses included 370 pts (n = 195 E, 117 G, and 58 C) with at least 1-yr follow up. 150 patients (45% E, 33% G, and 41% C) were alive at the end of 1-yr. Survival curves between E, G, and C differed significantly (Logrank p < 0.05; Wilcoxon p < 0.05). Censored median survival of E pts was 9.75 mons compared to 6.95 for G (p < 0.05) and 7.48 for C pts, respectively. CPH analysis adjusted for age, ethnicity, ECOG score, BMI, and adverse events showed significant survival benefit for E pts compared to G (HR = 0.71, p < 0.05), but no significant differences between E vs C or C vs G pts.
Conclusions
This real-world 1-yr survival analysis of pts with mBC and VM demonstrated significantly better OS for pts receiving E as compared to G, and a trend favoring OS for patients receiving E in comparison to C.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Eisai Inc.
Funding
Eisai Inc.
Disclosure
S.M. Kazmi: Speaker Bureau / Expert testimony: Eisai, Takeda, Lilly, Merck; Advisory / Consultancy: Merck, Takeda. E. Wang: Non-remunerated activity/ies, Eisai employee at the time of research: Eisai. R.S. Hauser: Research grant / Funding (institution): Eisai. P.A. Kaufman: Advisory / Consultancy, Research grant / Funding (institution), research grant support, and consulting fees: Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
4250 - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
Presenter: Erika Martinelli
Session: Poster Display session 2
Resources:
Abstract
5234 - The ORCHESTRA trial; A phase III trial of adding tumor debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC).
Presenter: Lotte Bakkerus
Session: Poster Display session 2
Resources:
Abstract
5294 - EMERGE: Epigenetic Modulation of the Immune Response in Gastrointestinal cancers
Presenter: Elizabeth Cartwright
Session: Poster Display session 2
Resources:
Abstract
913 - Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): subgroup analyses
Presenter: Margaret Tempero
Session: Poster Display session 2
Resources:
Abstract
1668 - FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma : update of the AGEO cohort.
Presenter: Edouard Auclin
Session: Poster Display session 2
Resources:
Abstract
2559 - Impact of adjuvant treatment with nab-paclitaxel and gemcitabine (nab-P+GEM) vs gemcitabine alone (GEM) on health-related quality of life (QoL) in patients (pts) with surgically resected pancreatic adenocarcinoma (PA) in the Adjuvant Pancreatic Adenocarcinoma Clinical Trial (APACT)
Presenter: Hanno Riess
Session: Poster Display session 2
Resources:
Abstract
4897 - Early detection of pancreatic ductal adenocarcinoma using methylation signatures in circulating tumor DNA
Presenter: Xiao-ding Liu
Session: Poster Display session 2
Resources:
Abstract
1755 - Evaluation of minimal important difference (MID) for the European Organisation for Research and Treatment of Cancer (EORTC) Pancreatic Cancer Module (PAN26) in patients with surgically resected pancreatic adenocarcinoma
Presenter: Michele Reni
Session: Poster Display session 2
Resources:
Abstract
2876 - Multispectral analysis of lymphocyte complexity in periampullary adenocarcinoma
Presenter: Sebastian Lundgren
Session: Poster Display session 2
Resources:
Abstract
1902 - Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Jae Ho Jeong
Session: Poster Display session 2
Resources:
Abstract